B. Riley Has Lowered Expectations for Geron (NASDAQ:GERN) Stock Price

Geron (NASDAQ:GERN) had its price objective lowered by research analysts at B. Riley from $5.50 to $3.50 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price objective suggests a potential upside of 33.33% from the company’s current price.

Several other equities analysts have also recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Geron in a research report on Tuesday, December 10th. Barclays upgraded Geron to a “strong-buy” rating in a research report on Friday, November 29th. Finally, Needham & Company LLC lifted their target price on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $6.91.

Geron Price Performance

NASDAQ:GERN traded up $0.07 during trading hours on Tuesday, reaching $2.63. 15,598,745 shares of the company were exchanged, compared to its average volume of 11,753,566. The company has a market capitalization of $1.59 billion, a P/E ratio of -8.20 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The business has a 50 day moving average of $3.21 and a 200 day moving average of $3.91. Geron has a 1-year low of $1.64 and a 1-year high of $5.34.

Hedge Funds Weigh In On Geron

Hedge funds and other institutional investors have recently made changes to their positions in the stock. RTW Investments LP bought a new stake in shares of Geron in the 3rd quarter valued at $200,268,000. Nvest Financial LLC acquired a new stake in Geron during the 4th quarter worth about $693,000. Janus Henderson Group PLC lifted its stake in shares of Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after purchasing an additional 13,163,889 shares during the period. Barclays PLC lifted its stake in shares of Geron by 114.9% in the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock valued at $5,902,000 after purchasing an additional 694,931 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Geron during the 3rd quarter valued at about $1,102,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.